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Abstract: Placebo analgesia is being increasingly appraised as an effective support of 
pharmacological and surgical treatments of pain. The understanding of its neurobiological 
and psychological basis is therefore of high clinical relevance. It has been shown that placebo 
analgesia is somatotopically organized and relies on endogenous opioids. However, it is not clear 
whether temporal fluctuations of cue-dependent spatial attention account for the site specificity 
of placebo analgesia or whether a somatotopic placebo effect is possible without an attentional 
focus on the respective location. To address this issue we induced placebo expectations for 
one specific foot in healthy subjects, the other foot serving as a control location. The feet were 
stimulated in random order by painful laser stimuli. Half of the pulses were cued for stimulus 
location, whereas in the other half of trials the subjects were naïve about the location. We found 
that about half of the subjects exhibited a somatotopic placebo effect that was statistically inde-
pendent of the spatial cue. We suggest that, after the induction of an initial expectation, placebo 
analgesia is spatially specific but does not necessarily depend on momentary fluctuations of 
spatial attention. This result rather suggests that the somatotopy of placebo analgesia relies on 
the creation of spatially guided expectations or conditioning, but can be maintained without 
ongoing monitoring of the affected body part.
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Introduction
Placebo analgesia is the pain relieving effect of an intrinsically inactive substance 
which is caused by the patient’s expectation of its effectiveness.1 Evidence led to the 
practical conclusion that placebo is no longer regarded a delusion of the patient but 
a potential to increase the effect of pharmacological or physical therapy.2 It has been 
shown that placebo analgesia strongly relies on prior experience and expectation of 
pain relief  3,4 and has been linked to opioidergic and nonopioidergic mechanisms.5 
Functional brain imaging studies revealed that placebo analgesia is indeed related 
to decreased activity in pain-related areas and increased activity in frontal regions 
including the anterior cingulate cortex.6–8
Placebo analgesia, and more generally endogenous analgesia, has traditionally 
been considered a phenomenon that affects the entire body without any site-specificity. 
However, Montgomery and Kirsch9 challenged this view by demonstrating that only 
pain in the body part that was expected to be treated responded to pain relief but not 
remote body areas. Later, Benedetti and colleagues10 showed that somatotopic mani-
festations of placebo relied on endogenous opiates. In addition, Watson et al11 who 
gave ambiguous information about the site of analgesia found a placebo effect that Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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was specific for one arm in some of their subjects while other 
subjects showed a bilateral response. However, as in these 
studies the subjects could anticipate the stimulus location, 
it is possible that trial-by-trial variation of spatial attention 
and not the existence of somatotopically organized descend-
ing pathways could have accounted for the observations 
described above. Therefore, the key question of the present 
study was: does the site-specificity of placebo analgesia 
depend on momentary fluctuations of spatial attention, or is 
its initiation by spatially guided expectancies sufficient for it 
to be maintained in the absence of spatial attention.
To investigate this question, we applied an inert cream to 
both feet while suggesting that one foot would be treated by 
a potent analgesic. We induced placebo cognitions for one 
specific foot and manipulated spatial attention by presenting 
either a visual cue that announced the location of the painful 
laser stimulus or a visual stimulus that did not inform about 
the location of stimulus application. If momentary variation 
of spatial attention induced by informative cues was crucial 
for the somatotopic organization of placebo analgesia, pain 
relief would appear only during trials with an informative 
cue. Alternatively, if spatial attention was not necessary for 
a spatially specific placebo effect, placebo responders would 
perceive less pain regardless of the cue.
Methods
Participants
Twenty-eight healthy volunteers (15 male) were paid to 
participate in this study. They were aged 20 to 34 years 
(mean 24 ± 3). Written informed consent was obtained and 
the subjects were informed that they could terminate the 
experiment at any time. The study was conducted according 
to the Declaration of Helsinki and approved by the local 
ethics committee. After finishing the project, subjects were 
debriefed by an information letter about the real purpose of 
the experiment. One subject was excluded from the analysis 
because of problems with the instructions.
Pain stimulus
For stimulation of the dorsum of the feet a Thulium YAG 
laser (wavelength 2 µm, StarMedTec, Starnberg, Germany) 
was used. The stimuli were brief infrared laser pulses of 
1 millisecond duration and a beam diameter of 5 mm. Before 
the experiment, individual pain thresholds were determined 
for the two feet separately using 3 series of increasing and 
decreasing stimuli. Beginning at 160 mJ we used a step size 
of 20 mJ. Pain was defined as a feeling of a light pinprick 
comparable to the pulling of a hair.
Procedure
The experimenter wore a white lab coat and informed the 
subjects that we were investigating the effect of a new 
analgesic cream containing lidocaine. In fact, an inactive 
cream was applied with a wooden applicator to the dorsa of 
both feet of the subjects while the experimenter wore surgical 
gloves. The subjects were told that the “analgesic” cream was 
applied to one particular foot, while the other foot was treated 
with an inactive cream as a control containing the same carrier 
substance without lidocaine. The site of placebo manipulation 
was further defined using a series of conditioning trials (see 
below) and counterbalanced across subjects.
During the experiment the subjects were seated in a com-
fortable chair in front of a computer screen. Their feet were 
positioned such that they were not able to see the location of 
the stimulus application. The design is illustrated in Figure 1. 
The experiment consisted of  2 conditioning blocks of 10 trials 
and 4 experimental blocks of  80 trials. At the beginning of each 
trial the subject was shown a visual cue for the stimulus loca-
tion on the screen. Two seconds later the laser pulse was deliv-
ered followed by a visual analog scale on the screen 3 seconds 
later. The subjects had to rate stimulus intensity by completing 
the scale using a joystick during the next 1.5 seconds. The lower 
end of the scale (0%) designated “no pain” while the upper end 
indicated “worst imaginable pain” (100%). During the condi-
tioning blocks the stimulus intensity delivered to the placebo 
foot was 1.5-fold pain threshold while the control site was 
stimulated with 2-fold threshold. Due to the fact that subjects 
were told that the applied intensity was the same for both feet, 
we expected placebo analgesia at the site where the subjects 
attributed the perception of lower intensity to a treatment effect. 
The two feet were stimulated in alternate order and in all trials 
the cue indicated the stimulation site. During the following 
4 experimental blocks, the stimulus intensity was identical 
(2-fold threshold) at both sites and stimuli were delivered in 
a fixed random order to both feet. Furthermore, in half of the 
trials, the arrow contained information about the stimulation 
location. In the other half of the trials, the arrow pointed to 
the top and thus did not contain information about where the 
stimulus would be presented. The cue design was chosen such 
that the subjects directed their attention spatially to the placebo 
and control sites after an informative cue in comparison with 
trials where no spatial information was given.
statistical analysis
To detect a placebo effect on the single subject level, t-tests 
were calculated to test for differences in the pain ratings 
between the placebo and the control condition. A significant Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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reduction in pain ratings in the placebo condition (critical 
P-value = 0.05) would indicate a placebo effect and subjects 
were classified as placebo responders. Subjects who did not 
exhibit any pain relief by the placebo treatment were classified 
as non-responders. The groups were compared for their pain 
ratings, thresholds, and age by nonparametric Mann–Whitney 
test. To make sure that there was a true overall placebo effect, 
a repeated-measures ANOVA was first calculated for the 
whole group including only the factor treatment (placebo, 
control). As we were specifically interested in the behavior of 
the placebo responders and its dependence on spatial atten-
tion, a repeated-measures ANOVA for the responder group 
was calculated including the within-subject factors treatment 
(placebo, control) and cue (informative, non-informative). 
Beforehand, normal distribution of all variables included in 
the ANOVA was confirmed by Kolmogorov–Smirnov test.
Results
single-subject statistics
Of the 27 subjects, 13 were classified as placebo responders 
(48%), as their pain ratings in the placebo condition were 
significantly lower than in the control condition (P-values 
ranging from ,0.01 to 0.04). Fourteen subjects (52%) did 
not show any significant relief due to the treatment and thus 
were classified as non-responders.
group statistics
Placebo responders did not differ from non-responders in age, 
pain threshold at the placebo and control foot, and ratings in 
the control condition.
The repeated-measures ANOVA revealed a significant 
treatment effect (F(1,25) = 11, P , 0.005) due to lower 
ratings in the placebo condition (38 ± 15) than in the control 
condition (41 ± 15). As expected, the separate analysis for 
the responder group also resulted in a significant treatment 
effect (F(1,12) = 67, P , 0.0001; Figure 2). In the placebo 
condition, the responders felt significantly less pain than in 
the control condition (32 ± 12 vs 42 ± 14). The effect of cue 
was not significant. Furthermore, the interaction between 
cue and treatment did not reach significance, indicating that 
the treatment effect did not depend on spatial attention.
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Figure 1 experimental design. A) An inert cream was applied to both feet while subjects were told that one particular foot was treated by lidocaine. B) During the conditioning 
blocks, low intensity laser pulses were delivered to the placebo foot while the control foot was stimulated by high intensity pulses. All trials contained a cue about the stimulus 
location. During the experimental blocks, both feet were stimulated by high intensity laser pulses and only half of the trials contained information about the stimulus location.   
C) At the beginning of the trial, a visual cue (informative vs non-informative) preceded the laser stimulus that had to be rated on a visual analog scale 3 seconds later.
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Figure 2 group statistic for the placebo responders. Pain ratings in the placebo 
condition are significantly lower than in the control condition. Note that the relief 
by the placebo treatment is independent of the type of cue.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Discussion
This study attempted to clarify whether momentary fluctua-
tions of pain suppression by cue-induced expectations can 
explain the site-specificity of placebo analgesia. We treated 
the feet of our subjects by a placebo and a control cream. Con-
ditioning trials in which the subjects attributed a difference of 
applied laser stimulus intensity to a pretended treatment effect 
served to induce placebo cognitions. About half of the subjects 
were placebo responders in subsequent experimental blocks 
of identical stimulus intensities applied to both feet. Our 
results support earlier findings of Montgomery and Kirsch9 
and Benedetti et al10 that placebo analgesia is somatotopically 
organized. Furthermore, the major result of our study was that 
spatially informative and non-informative visual cues failed 
to affect the somatotopy of the placebo effect.
We induced top-down expectations of analgesia at the 
beginning of the experiment using verbal suggestion and 
conditioning. This has been reported useful in former 
studies3,4 and to rely on opioid mechanisms.5 Verbal sugges-
tion seems to be crucial for the spatial specificity of placebo 
analgesia, as Watson et al11 did not inform their subjects about 
the treatment site, resulting in a group of bilateral placebo 
responders. Our design does not allow ruling out that part of 
our non-responders exhibited a bilateral pain decrease. How-
ever, this seems unlikely, as the non-responders did not differ 
from the responders in their ratings in the control condition, 
ie, they gave high pain ratings in both treatment conditions. 
Our procedure might additionally have contributed to the idea 
that even very short painful laser stimuli can be sensitive to 
placebo analgesia, although other authors argued that placebo 
acts only on long-lasting pain perception.12,13
The absence of an interaction with cue-dependent spatial 
attention suggests indirectly a somatotopic organization of 
a subcortical route of pain modulation that interacts with 
spatially guided expectations or conditioning underlying the 
site specificity of placebo analgesia. It is known that brain-
stem structures such as the periaquaeductal grey (PAG) are 
involved in descending inhibition of pain at the dorsal horn 
level (for a review see14). PAG stimulation has been shown 
to induce analgesia for several weeks that was naloxone 
reversible, and thus depended on opioid mechanisms.15 
Furthermore, a rough somatotopy has been demonstrated 
that affected distinct extremities16 and upper versus lower 
body parts17 differently. Therefore, placebo analgesia that is 
specific for one foot and lasts throughout an experiment of 
1 hour can possibly be mediated by this structure.
Functional brain imaging studies demonstrated the 
involvement of prefrontal networks during   anticipation and 
processing of pain stimuli after the induction of   placebo 
analgesia.6,7 These studies showed that activity in   frontal 
regions such as the anterior cingulate gyrus7 and the 
prefrontal/orbitofrontal cortex,6 engaged during attention 
and expectation, was related to placebo analgesia, and cor-
related with increased activity in the brainstem PAG. This 
fits with findings that frontal regions and midbrain structures 
share common opioidergic mechanisms related to placebo 
analgesia.18,19 Wager et al6 and Bingel and colleagues7 dem-
onstrated by event-related functional magnetic resonance 
imaging during cues of pain stimulation at placebo and 
control sites that frontal regions, such as the dorsolateral 
prefrontal cortex (DLPFC), processing top-down informa-
tion about the stimulus, initiate the descending inhibition 
by the PAG in a phasic manner. Recently, low-frequency 
repetitive transcranial magnetic stimulation of the DLPFC 
has been found to completely block placebo analgesia.20,21 
One might therefore expect – according to the alternative 
hypothesis of our study – that a phasic mode of spatial atten-
tion can account for the site specificity of placebo analgesia. 
In their elegantly designed study, Benedetti et al10 applied 
a tonic pain stimulus simultaneously to both feet and hands 
using subcutaneous injections of capsaicin via a computer-
controlled injection pump. One or two of these sites were 
treated by a placebo cream. Electrical pulses announced the 
location at which pain had to be rated by the subjects. These 
cues occurred every 7 seconds. The spatial specificity of 
placebo analgesia that the authors observed could therefore 
be the result of a temporal fluctuation of pain suppression 
by expectancy between successive cues, governed by the 
DLPFC, without being necessarily dependent on a soma-
totopic organization of the descending pathway. However, 
although our results are compatible with the assumption that 
the DLPFC is important to engage endogenous inhibition 
during placebo analgesia, the somatotopy of the network is 
likely represented in different areas, probably primary and 
secondary somatosensory cortices and subcortical areas 
such as the brainstem.
The absence of any cue effect can be considered a 
weakness of our study. Attention in general and cuing 
in particular has been repeatedly found to affect pain 
perception.22–24 As we did not find an effect of the visual 
cue on pain perception one can argue that we cannot be 
sure about the effectiveness of our attentional manipulation. 
However, the typical amplification of pain by a valid cue 
would contradict the placebo effect and the two effects would 
cancel each other out. Therefore, one could not expect to 
find a main effect of the cue but only an interaction between Journal of Pain Research
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the placebo treatment and spatial attention for which we had 
been looking.
Conclusion
As we did not observe a dependence of spatially specific 
placebo analgesia on a spatial cue, we conclude that soma-
totopically organized placebo analgesia is possible without 
spatial attention. We suggest that a spatially specific expecta-
tion of analgesia that is induced in the beginning is sufficient 
to recruit the frontal attention network. In turn, this network 
initiates the endogenous antinociceptive system, especially 
the brainstem PAG, which maintains the spatial information 
for a longer time by means of its own somatotopic organiza-
tion. Therefore, a trial-by-trial fluctuation of spatial attention 
is not necessary.
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